Enfermedad del suero-like asociada a clopidogrel

Titos-Arcos, JC; Plaza-Aniorte, J; Nájera-Pérez, M.D.; Sánchez-Quiles, I.

doi:10.1016/s1130-6343(08)72828-9

Search citation statements

Order By: Relevance

Paper Sections

Select...

Ta B L E 2 (Continued)1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2010

2021

Publication Types

Select...

Book2

Article1

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The patients could tolerate ticagrelor, ticagrelor and ticlopidine completely, with the resolution of arthritis and with no recurrence of arthritis. 7,9,10,[15][16][17][18] Although the postmarketing report of ticagrelor states that ticagrelor has been shown to be related to gout/gouty arthritis, the mechanism by which this occurs is different from the mechanism of clopidogrel-induced arthritis. 29 Ticlopidine has a chemical structure similar to clopidogrel and has been reported to cause acute arthritis, suggesting a possible class effect.…”

Section: Ta B L E 2 (Continued)mentioning

confidence: 99%

Analysis of the clinical characteristics of acute arthritis induced by clopidogrel

Sun

Zhou

et al. 2021

J Clin Pharm Ther

View full text Add to dashboard Cite

Clopidogrel is a second-generation thienopyridine that was approved for marketing in the United States (US) in 1998. Clopidogrel covalently binds to the P2Y12 receptor, which is the main platelet receptor responsible for ADP-induced platelet aggregation, leading to irreversible platelet inhibition. 1 Clopidogrel is absorbed in the gastrointestinal tract by the drug efflux transporter P-glycoprotein,

show abstract